Pasithea Therapeutics Corp. (KTTA) Tuesday announced that FDA has accepted its Investigational New Drug Application or IND clearance to evaluate PAS-004 in patients with MAPK pathway-driven advanced solid tumors.
In the pre-market session, shares are gaining more than 6 percent on the Nasdaq.
Pasithea expects to dose the first patient in the first quarter of 2024.
PAS-004 is a macrocyclic MEK 1/2 inhibitor. The study targets patients with documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition.
PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials and is expected to be an oral, once-day or less frequent dose.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.